Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Restructuring Costs (2016)

Historic Restructuring Costs for Ligand Pharmaceuticals (LGND) over the last 5 years, with Q4 2016 value amounting to $169000.0.

  • Ligand Pharmaceuticals' Restructuring Costs fell 2777.78% to $169000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $1.0 million, marking a year-over-year increase of 117.65%. This contributed to the annual value of $1.0 million for FY2016, which is 117.65% up from last year.
  • As of Q4 2016, Ligand Pharmaceuticals' Restructuring Costs stood at $169000.0, which was down 2777.78% from $245000.0 recorded in Q3 2016.
  • Ligand Pharmaceuticals' 5-year Restructuring Costs high stood at $562000.0 for Q4 2014, and its period low was $44000.0 during Q2 2013.
  • In the last 5 years, Ligand Pharmaceuticals' Restructuring Costs had a median value of $223000.0 in 2015 and averaged $243736.8.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Restructuring Costs crashed by 8937.2% in 2013 and then surged by 20909.09% in 2014.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Restructuring Costs stood at $356000.0 in 2012, then plummeted by 43.54% to $201000.0 in 2013, then skyrocketed by 179.6% to $562000.0 in 2014, then plummeted by 58.36% to $234000.0 in 2015, then dropped by 27.78% to $169000.0 in 2016.
  • Its last three reported values are $169000.0 in Q4 2016, $245000.0 for Q3 2016, and $374000.0 during Q2 2016.